Weitai Bio, a company spun out from Shalier Bio, has secured over $50 million in Series A and A+ funding. The company is advancing its lead drug candidate, GT801, which utilizes a lipid nanoparticle (LNP) delivery system for in vivo CAR-T therapy. Preliminary human data presented at the AACR annual meeting showed GT801 effectively cleared B cells in patients with hematological malignancies and autoimmune diseases, demonstrating the feasibility of repeat dosing. AI
Summary written by gemini-2.5-flash-lite from 1 source. How we write summaries →
IMPACT Advances in in vivo CAR-T therapy using LNP delivery could accelerate development for autoimmune diseases and certain cancers.
RANK_REASON Company secures significant funding and presents preliminary human data for a novel therapeutic approach.